Abstract We here demonstrate that the anti-diabetic drug metformin interacts synergistically with the anti-HER2 monoclonal antibody trastuzumab (Tzb; Herceptin TM ) to eliminate stem/progenitor cell populations in HER2-geneamplified breast carcinoma cells. When using the mammosphere culture technique, graded concentrations of single-agent metformin (range 50-1,000 lmol/l) were found to dose-dependently reduce the number of mammospheres formed by SKBR3 (a Tzb-naïve model), SKBR3 TzbR (a model of acquired auto-resistance to Tzb) and JIMT-1 neg/low stem/progenitor immunophenotype. Given that MSFE and mammosphere size are indicators of stem self-renewal and progenitor cell proliferation, respectively, our current findings reveal for the first time that: (a) Tzb refractoriness in HER2 overexpressors can be explained in terms of Tzb-resistant/CD44-overexpressing/ tumor-initiating stem cells; (b) metformin synergistically interacts with Tzb to suppress self-renewal and proliferation of cancer stem/progenitor cells in HER2-positive carcinomas.
Introduction
For decades, breast cancer (BC) initiation and progression has been regarded as a multistep process that is reflected by the progressive genetic alterations that drive the transformation of normal human cells into highly malignant derivatives [1] . In recent years, the experimental demonstration of tumor-initiating cells (popularly known as cancer stem cells) rather supports tumor hierarchy as a fundamental concept in the biology of BC disease [2] . According to the cancer stem cell hypothesis, primary BC contain subpopulations of replenishing stem-like cells (i.e., tumor-initiating cells) with the ability of both self-renew and give rise to phenotypically diverse progeny [3] . In other words, solely the tumor-initiating cells have the ability to proliferate extensively, give rise to differentiated cells and form new tumors. When using cytotoxics or radiation, the bulk BC cell population decreases, but the proportion of tumor-initiating cells is higher than before treatment, thus indicating that conventional therapeutics efficiently kill differentiated BC cells whereas BC stem cells, by their nature, are intrinsically refractory thereby allowing BC regrowth [4, 5] . The fact that tumor-initiating cells display intrinsic resistance to many conventional treatments might therefore explain the current limitations of these therapeutic approaches in curing breast BC.
Although many novel molecularly targeted agents (e.g., monoclonal antibodies, tyrosine kinase inhibitors [TKIs] , etc.) have been also designed to target rapidly proliferating BC cancer cells-so many tumor-initiating cells might also be relatively insensitive to these agents-we are beginning to accumulate evidence that anti-HER2 therapeutics can effectively target tumor-initiating cells derived from HER2-overexpressing BC [5, 6] . In analogy with genes such as Notch, Hedgehog, Wnt, and ras, initially identified as oncogenes, but shown subsequently to be actively involved in self-renewal and survival of tumor-initiating cells, HER2 may also constitute a pivotal molecule in BC stem cells. The notion that HER2 signaling can drive tumor-initiating cells in certain HER2-positive BC is supported by the following findings: (1) HER2 overexpression in multiple BC cell lines significantly increases the fraction of cells positive for ALDH1 (aldehyde dehydrogenase) [7] -a marker of normal and cancerous human mammary epithelial cells with stem/progenitor properties-and enhances the tumor-initiating component that drives tumorigenesis, invasion, and metastasis [8] ; (2) Pioneering findings by Li et al. demonstrated that, conversely to chemotherapy treatment, the epidermal growth factor receptor (EGFR)/HER2 dual TKI lapatinib, decreases the subpopulation of chemotherapy-resistant BC initiating cells (measured by calculating the percentage of cells with the CD44 pos /CD24 neg/low stem/progenitor immunophenotype and the ability to form mammospheres in vivo as an indication of self-renewal) [5] ; and (3) Tumor-initiating cells of HER2-positive BC have been shown to express the highest HER2 levels and been sensitive to the anti-HER2 monoclonal antibody trastuzumab (Tzb; Herceptin TM ) [6] . Intriguingly, recent observations have suggested also that clinical resistance to Tzb and other HER2-targeted therapies may be driven by stem-like BC cells within HER2-positive BC. Indeed, a variety of possible mechanisms of escape from Tzb involves many of the same markers that have been implicated in the biology of cancer stem cells (e.g. loss or blockade of the Tzb binding site at the extracellular domain of HER2 upon overexpression of the stem cell marker CD44, signaling through alternative receptor pathways via the stem cell markers CXCR4 and b1 integrin, activation of Notch signaling to promote Tzb resistance via enhanced self-renewal/proliferation of progenitor cells or induction of epithelia-to-mesenchymal transition, etc.) [Reviewed in 9]. Therefore, a major challenge now is: (1) to define the sensitivity of the sub-population of tumorinitiating (BC stem) cells to current and novel anti-HER2 BC therapies and (2) to discover agents and strategies that can target HER2-positive BC and HER2-positive BC relapse at their apparent source of tumor-initiating (BC stem) cells.
Culturing BC cells in so-called ''mammosphere culture'' has been proposed as a reliable method for enriching sub-populations of putative BC tumor-initiating stem cells [10] . Mammosphere culture could provide a highly appropriate model for studying the sensitivity of the tumor-initiating stem cells within a heterogeneous BC cell population to therapeutic agents. Thus, a comparison of efficacy using mammospheres from BC cells lines or mammospheres cultured from individual pleural effusions as targets would allow evaluation of the consistency of effectiveness of a specific therapy. Taking advantage of the ability of BC stem cells to form multicellular ''microtumors'' in non-adherent and non-differentiating conditions (i.e., ''mammospheres'' [11, 12] ) and considering novel data showing the unexpected ability of the anti-diabetic drug metformin to preferentially kill BC stem cells [13] , we recently decided to explore if metformin may alter self-renewal and proliferation of tumor-initiating stem cells in BC in vitro models representative of Tzbresponsive and Tzb-refractory HER2-gene-amplified BC disease. We have assessed also, at the level of mammosphere-initiating cells, the relevance of well-recognized BC stem cell markers (i.e., CD44) in the phenomena of both acquired and de novo refractoriness to the anti-HER2 monoclonal antibody Tzb. Finally, we have explored the nature of the (anti-BC stem cell) interaction (i.e., antagonism, addition, and synergism) between metformin and Tzb in Tzb-naïve and Tzb-refractory HER2-overexpressing BC models.
Materials and methods

Materials
Trastuzumab (Herceptin TM ) was provided by Pharmacy Department, Hospital Universitario de Girona Dr. Josep Trueta (Girona, Spain), solubilized in bacteriostatic water for injection containing 1.1% benzyl alcohol (stock solution at 21 mg/ml), stored at 4°C and used within 1 month. Metformin hydrochloride (1,1-dimethylbiguanide hydrochloride) was purchased from Sigma Chemical (St. Louis, MO, USA), solubilized in phosphate-buffered saline (PBS; stock solution at 1 mol/l), stored at -20°C and used within 2 weeks.
Culture conditions SKBR3, MDA-MB-468, and MDA-MB-231 human breast cancer cells were obtained from the American Type Culture Collection (ATCC), and they were routinely grown in Improved MEM (IMEM; BioSource International; Invitrogen S.A., Barcelona, Spain) supplemented with 5% fetal bovine serum (FBS) and 2 mM L-Glutamine. SKBR3 TzbR cells (POOL1), an in vitro model with acquired autoresistance to Tzb that grows in the continuous presence of 100 lg/ml Tzb, has been developed in our laboratory as previously described [14] . JIMT-1 human breast cancer cell line was established at Tampere University from a ductal carcinoma pleural metastasis of a 62-year-old-BC patient who did not respond to Tzb [15] . JIMT-1 cell line is available from the German Collection of Microorganisms and Cell Cultures (http://www.dsmz.de/). JIMT-1 cells were grown in F-12/DMEM (1:1) supplemented with 10% FBS and 2 mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Cells were screened periodically for Mycoplasma contamination.
Mammosphere culture Mammospheres were generated from single cells of SKBR3, SKBR3 TzbR, and JIMT-1 cell lines seeded at 10 3 cells/cm 2 in six-well ultralow attachment plates (Corning Inc.). Sphere medium (F-12/DMEM containing 5 mg/ml insulin, 0.5 mg/ml hydrocortisone, 2% B27 (Invitrogen Ltd.), and 20 ng/ml epidermal growth factor) was prepared as originally described by Dontu et al. [11] .
Mammosphere-forming efficiency
Mammosphere-forming efficiency (MSFE) was calculated as the number of spheres-like structures (large diameter [50 lm) formed in 7 days divided by the original number of cells seeded and expressed as percentage means (±SD).
Flow cytometry
Cell cultures growing in regular medium (or supplemented with Tzb and/or metformin as specified), were washed once with phosphate-buffered saline (PBS) and then harvested with 0.05% trypsin/0.025% EDTA into single cell suspensions. Detached cells were washed with PBS containing 1% FBS and 1% penicillin/streptomycin (wash buffer), counted, and resuspended in the wash buffer (10 6 cells/100 ll). Combinations of fluorochrome-conjugated monoclonal antibodies obtained from BD Biosciences (San Diego, CA, USA) against human CD44 (FITC; cat.#555478) and CD24 (PE; cat.#555428) or their respective isotype controls were added to the cell suspension at concentrations recommended by the manufacturer and incubated at 4°C in the dark for 30-40 min. Labeled cells were washed in the wash buffer to eliminate unbound antibody, then fixed in PBS containing 1% paraformaldehyde, and then analyzed no longer than 1 h post-staining on a BD FacScalibur (BD Biosciences).
Statistical analysis
Results are presented as the mean ± SD for at least three repeated individual experiments for each group. Analysis was done using XLSTAT 2010 (Addinsoft TM ). P B 0.01 was considered statistically significant.
Results
Metformin is as efficient as Tzb at reducing MSFE in Tzb-naïve SKBR3 BC cells
The mammosphere culture technique was employed to assess whether Tzb and metformin, as single agents, may significantly reduce MSFE in Tzb-naïve SKBR3 BC cells (Fig. 1a) . A clinically relevant concentration of Tzb was sufficient to significantly decrease MSFE in HER2-overexpressing SKBR3 cells (*35% MSFE reduction at 10 lg/ ml Tzb; Fig. 1b ). Similarly, a 35% MSFE reduction was obtained when sphere cultures of SKBR3 cells were carried out in the presence of 100 lmol/l metformin (Fig. 1b) . Indeed, a dose-dependent reduction of MSFE was clearly observed when SKBR3 cells were cultured in sphere medium supplemented with graded concentrations of metformin (up to 75% reduction at 1000 lmol/l metformin; Fig. 1a, b) . Remarkably, metformin treatment not only reduced MSFE but also caused further morphological changes to SKBR3 mammospheres. Thus, SKBR3 mammospheres formed in the presence of 50 and 100 lg/ml metformin exhibited a significant disintegration of the spherical mammospheres structures observed in untreated SKBR3 control cells (Fig. 1a) . When sphere cultures of SKBR3 cells were carried out in the presence of concurrent Tzb and metformin, we observed mostly additive interactions of both agents when analyzing fold-reductions of MSFE in SKBR3 cells (Fig. 1c) . pressure of Tzb to drive the emergence of ''Tzb-resistant'' HER2-positive BC stem/progenitor cells [9] . In order to evaluate this hypothesis, we took advantage of SKBR3 TzbR cells (POOL1), which were obtained in our laboratory by continuously culturing HER2-dependent SKBR3 parental cells in the presence of high-doses of Tzb for more than 10 months [14] . This Tzb-conditioned SKBR3 derivative optimally grows in the presence of 100 lg/ml Tzb. Unlike Tzb-sensitive SKBR3 parental cells, which formed discrete and spherical mammospheres, SKBR3 TzbR cells cultured in sphere medium formed larger and irregular mammosphere-like structures (Fig. 2a) . In order to evaluate whether changes in gross mammosphere structure related to changes in the expression of the stem cell markers involved also in Tzb resistance, we employed flow cytometry to examine cell surface distribution of CD24 and CD44 markers before and after acquisition of Tzb auto-resistance. Tzb-naïve SKBR3 parental cells likewise exhibited a significantly enriched CD24 pos /CD44 neg (*90%) cell population, which is consistent with the luminal-type classification of SKBR3 BC cells (Fig. 2a, left) . Interestingly, 55% of the SKBR3 TzbR cell population displayed a CD24 pos /CD24 pos immunophenotype, which to some extent resembled the CD24/CD44 distribution that can be observed in highly metastatic MDA-MB-468 basal-like BC cells (Fig. 2a, right) . Moreover, mammosphere-initiating cells within SKBR3 TzbR cell populations did exhibit resistance to Tzb as MSFE remained largely unaltered when by SKBR3 TzbR cells growing in sphere medium for 7 days in the absence or presence of 100 lg/ml Tzb and co-exposed to increasing concentrations of metformin, as specified (109 magnification). c, d SKBR3 TzbR MSFE and fold-decreases of MSFE observed in SKBR3 TzbR cells growing in sphere medium supplemented with Tzb in the absence or in the presence of graded concentrations of metformin were calculated as in Fig. 1b and 
SKBR3 TzbR sphere cultures were performed in the presence of Tzb doses as high as 100 lg/ml (Fig. 2b, c) .
Metformin interacts synergistically with Tzb at reducing MSFE in HER2-overexpressing BC cells with acquired resistance to Tzb
In light of these findings, we sought to assess whether metformin could reverse acquired auto-resistance to Tzb by targeting ''Tzb-resistant'' HER2-positive BC stem/progenitor cells. Of note, Tzb-refractory mammosphere-initiating cells were exquisitely sensitive to metformin. A total of 100 lmol/l metformin reduced MSFE by about 50% while 1,000 lmol/l metformin completely suppressed mammosphere formation in SKBR3 TzbR cells (Fig. 2a, b) . Moreover, synergistic interactions between Tzb and metformin were found throughout the entire range of metformin concentrations (Fig. 2c) . Thus, the ability of 500 lmol/l metformin to decrease SKBR3 TzbR MSFE increased from about five times when used as single-agent to more than 17 times when combined with Tzb.
Metformin interacts synergistically with Tzb to reduce MSFE in JIMT-1 BC cells, an in vitro model of refractoriness to HER2-targeted therapies ab initio
In order to validate further the notion that metformin may attack Tzb-resistant tumor-initiating stem cells, we took advantage of the de novo Tzb resistance in a cell line (JIMT-1) isolated from the pleural fluid of a HER2-positive BC patient with progressive disease on Tzb [15] . Unlike Tzb-sensitive HER2-overexpressing SKBR3 cells and similarly to SKBR3 TzbR cells with acquired auto-resistance to Tzb, Tzb-refractory JIMT-1 cells cultured in sphere medium for 7 days formed irregular and somewhat loosely adhered clumps of cells (Fig. 3a) . Although treatment with single-agent Tzb reduced both the number and the size of JIMT-1 mammosphere-like structures, Tzb-induced reduction of JIMT-1 MSFE was not statistically significant (Fig. 3b, c) . These findings support further the notion that refractoriness to Tzb in HER2-positive BC cells can be explained in terms of BC stem/progenitor populations intrinsically resistant to Tzb. In this scenario, treatment with single-agent metformin was sufficient to drastically reduce MSFE in Tzb-refractory JIMT-1 cells (*65% MSFE reduction at 100 lmol/l metformin; Fig. 3b, c) . Perhaps more importantly, concurrent combination of Tzb and metformin worked synergistically to totally suppress the ability of JIMT-1 cells to form mammospheres. Thus, the ability of 1,000 lmol/l metformin to decrease MSFE increased from about five times when used as single-agent to more than 22 times when combined with Tzb (Fig. 3c) . neg/low progeny, and (2) whether concomitant exposure to Tzb and metformin significantly affected the BC stem CD44 pos /CD24 neg/low immunophenotype. When using JIMT-1 cells from cultures passages #20 to #30, flow cytometry analyses clearly revealed a significant subpopulation of about 70% of JIMT-1 cells naturally exhibiting the CD44 pos /CD24 neg/low BC stem profile (Fig. 3d) . Rather than exhibiting a luminal-type classification, the unique distribution of CD24 and CD44 markers in HER2-geneamplified JIMT-1 cells somewhat resembled that observed in CD44 pos /CD24 neg/low -enriched MDA-MB-231 mesenchymal BC cells (Fig. 3a) . Then, we assessed distribution of the cell surface markers CD24 and CD44 in JIMT-1 cells following treatment (48 h) with two concentrations of metformin (i.e., 100 and 1,000 lmol/l) in the absence or in the presence of an optimal dose (100 lg/ml) of Tzb (Fig. 3d) . Whereas single-agent Tzb failed to significantly reduce the number of JIMT-1 cells exhibiting the putative stem-like CD44 pos CD24
neg/low immunophenotype, CD44 pos CD24 neg/low cell numbers were reduced by *30% upon treatment with 1,000 lg/ml metformin. Concurrent treatment with Tzb and 1,000 lmol/l metformin reduced neg/low stem/progenitor sub-population is highlighted (dashed red line). Tzb Trastuzumab, MET Metformin, Scale bars: 100 lm further, in a synergistic fashion, CD44 pos CD24 neg/low cell numbers (from 68% in untreated control cells to 37% in Tzb ? metformin co-treated cells) to concurrently increase the CD44 pos /CD24 pos fraction (from 32% in untreated control cells to 62% in Tzb plus metformin co-treated cells; Fig. 3d) .
In order to exclude that synergistic reduction of MSFE efficiencies in Tzb-refractory SKBR3 TzbR and JIMT-1 cells would simply reflect a generalized reduction in cellular viability, we replicated all the experimental groups in adherent conditions and cell growth was monitored by MTT assay. At the doses employed in sphere cultures, Tzb and metformin were ineffective at inhibiting cell growth of SKBR3 TzbR and JIMT-1 differentiated cultures routinely grown in plastic (data not shown).
Discussion
Hirsch et al. have recently demonstrated that tumor-forming, self-renewing BC stem cells appear to exhibit an exacerbated sensitivity to the anti-diabetic drug metformin [13] . In their hands, concurrent treatment with metformin (100 or 300 lmol/l) and the cytotoxic doxorubicin was found to reduce tumor mass and prevent relapse much more effectively than either drug alone in a xenograft mouse model. Here, using three HER2-gene-amplified BC in vitro models for Tzb-sensitivity (SKBR3), acquired Tzb auto-resistance (SKBR3 TzbR) and de novo Tzb refractoriness (JIMT-1), and employing mammosphere-forming efficiency and mammosphere size as indicators of stem self-renewal and progenitor cell proliferation, respectively, we provide for the first time pre-clinical evidence for the efficacy of the anti-diabetic drug metformin (50-100 lmol/l) to efficiently target Tzb-resistant tumor-initiating stem cells in HER2 overexpressors. We also confirm recent findings by Magnifico et al. showing that tumor-initiating cells of HER2-positive carcinoma cell lines are sensitive to the anti-HER2 monoclonal antibody Tzb [6] . Therefore, our findings corroborate and expand further Hirsch and Magnifico pioneer's findings to the combination of metformin with Tzb against HER2-positive tumor-initiating BC stem cells.
First, we confirmed the distinctive ability of the antidiabetic drug metformin to attack BC tumor-initiating stem cells within a heterogeneous population of BC cells overexpressing HER2. It should be noted that metformin concentrations as low as 50 lmol/l were sufficient to mimic the therapeutic effects of Tzb against mammosphere-initiating cells in Tzb-naïve SKBR3 cells. Although the remarkable potency to eliminate stem/progenitor cells in sphere cultures of HER2 overexpressors became obvious when analyzing dose-dependent decreases in MSFE of SKBR3 sphere cultures supplemented with graded doses of metformin, it was relevant also that metformin caused gross morphological changes in mammosphere structure. It is reasonable to suggest that, during formation of multicellular ''microtumors'', metformin treatment may actively interfere with the basic processes of differentiation and/or apoptosis in the stem/progenitor cell population of Tzbnaïve, HER2-overexpressing BC cells.
Second, our current findings provide a novel scenario for the molecular understanding of Tzb resistance in HER2 gene-amplified BC (Fig. 4) . The acquisition of Tzb resistance upon chronic exposure to Tzb can be explained in terms of emerging ''Tzb-resistant'' CD44-positive BC stem/progenitor cells because, in our hands, SKBR3 TzbR mammosphere-initiating cells did not respond to Tzb exposure. Our current findings strongly suggest that during [6, 7, 9] . Conversely, BC stem cells may be also at the root of resistance to Tzb. On the one hand, molecular characteristics of HER2-positive BC stem cells (e.g., expression levels of the stem cell marker CD44) may evolve under the selection pressure of Tzb, driving the selection and/or emergence of a sub-population of HER2-positive BC stem cells with acquired resistance to Tzb. On the other hand, the induction of the epithelial-mesenchymal transition (EMT) cellular program (prior or during Tzb challenge) may generate HER2-positive cells with stem-like features, such as the Tzb-refractory CD44 pos CD24 neg/low phenotype. Pro-survival mediators of BC stem cell resistance to Tzb appear to be exquisitely sensitive to the antidiabetic drug metformin thus eliciting additive and supra-additive inhibitory interactions between metformin and Tzb against HER2-positive BC stem cells. Beyond providing an explanation for Tzb treatment failure, our current findings provide a strong rationale for studying the clinical relevance of yet to be defined metformintargeted BC stem-cell maintenance pathways in combination with Tzb acquisition of auto-resistance to Tzb (i.e., secondary resistance to Tzb), HER2-overexpressing luminal BC cells appear to undergo a transition to basal-like phenotypes characterized by a significant enrichment in cell populations overexpressing the stem-cell marker CD44. This CD44-related scenario for Tzb refractoriness was even more apparent in HER2-gene-amplified BC cells with de novo resistance to multiple HER-targeted therapies. JIMT-1 BC cells not only exhibit primary resistance to Tzb but also demonstrate further cross-resistance to several HER2-inhibiting drugs including the HER-dimerization inhibitor antibody pertuzumab (2C4) and the small molecule tyrosine kinase inhibitors (TKIs) CI1033 (canertinib) and ZD1839 (gefitinib). Preliminary experiments in our laboratory demonstrated that JIMT-1 cells display also crossresistance to the dual HER1/HER2 TKI lapatinib (data not shown). Given that Tzb treatment has been shown to fail at decreasing the fraction of JIMT-1 cells positive for ALDH1 [7] , it has been suggested that BC stem cell-like phenotypes may underlie Tzb resistance in JIMT-1 cells [9] . In this regard, we have validated the notion that Tzbrefractory HER2-positive JIMT-1 cell cultures contain a significant population bearing the CD44 pos CD24
neg/low phenotype initially described by Al-Hajj et al. as a feature of BC stem cells that associates with the expression of basal/mesenchymal or myoepithelial markers [2] . Because earlier studies have repeatedly confirmed that all BC cell lines with significant CD44 pos /CD24 neg/low subpopulation belong to the basal type of BC and display the phenotype of cancer cells that have undergone epithelial to mesenchymal transition (EMT) [17, 18] , the unique distribution of CD24 and CD44 cell surface markers in HER2-overexpressing JIMT-1 cells may suggest that the induction of EMT in HER2-positive BC cells may generate cells with stem-like features, such as the CD44 pos /CD24 neg/low phenotype and the ability to grow in the presence of HER2 inhibitors. In this regard, it is noteworthy that JIMT-1 cells failed to produce discrete and correctly organized spherical structures, but rather formed somewhat loosely adhered clumps of cells when cultured in sphere medium for 7 days, a mammosphere-like architecture that has been observed in sphere cultures of CD44 pos /CD24 neg/low -enriched HER2-negative MDA-MB-231 mesenchymal BC cells [10] .
Third, mammosphere-initiating cells from both CD44-overexpressing SKBR3 TzbR cells with acquired autoresistance to Tzb and CD44-overexpressing JIMT-1 cells with de novo resistance to Tzb retained an exquisite and somewhat exacerbated sensitivity to the inhibitory effects of metformin. It has previously been shown that mammosphere number reflects stem cell self-renewal, whereas mammosphere size reflects progenitor cell proliferation [11, 12] . Our current findings reveal that Tzb treatment may affect stem/progenitor cell proliferation in Tzb-refractory HER2-gene-amplified BC because it significantly reduced mammosphere size. The incapability of Tzb to significantly decrease mammosphere cell number strongly suggests that Tzb efficacy in HER2-overexpressors rather relates to its ability to block HER2-driven stem/progenitor cell selfrenewal. Of note, metformin co-treatment synergistically worked with Tzb to suppress self-renewal and proliferation of Tzb-refractory tumor-initiating cells. In this scenario, it would be tempting to suggest that metformin-targeted crucial survival mechanisms may underlie also Tzb resistance in tumor-initiating cells because concurrent combination of metformin with Tzb synergistically reduced MSFE as well as mammosphere size in Tzb-refractory SKBR3 TzbR and JIMT-1 cells. Given that the percentage of CD44 pos / CD24 neg/low tumor-initiating cells has been shown to significantly correlated with MSFE in BC [5] and that co-treatment with metformin and Tzb synergistically reduced the percentage of JIMT-1 cells exhibiting the CD44 pos /CD24 neg/low stem/progenitor immunophenotype, it would be relevant to elucidate whether, in the presence of metformin, ''Tzb-resistant'' BC stem/progenitor cells may regain sensitivity to Tzb.
In summary, we present the first evidence that the antidiabetic drug metformin synergistically interacts with molecularly targeted agents, such as Tzb to suppress selfrenewal (measured as MSFE) and proliferation (evaluated as mammosphere size) of tumor-initiating (BC stem) cells of HER2-positive carcinoma cells showing acquired and de novo resistance to Tzb. The therapeutic plasma levels of metformin in clinical medicine are 0.465-2.5 mg/ml, whereas we observed statistically significant reductions in MSFE and mammosphere size in 50-1000 lg/ml metformin, a minimum 3-fold excess over the recommended therapeutic levels. Although the range of concentrations employed in our current approach were significantly lower than those used in earlier studies exposing cultures of differentiated cancer cells to metformin concentrations ranging from 1 to 100 mmol/l, forthcoming studies should validate whether concentrations of metformin capable of efficiently eliminating mammosphere-initiating cells might be also attained during breast cancer treatment. Although it has been reported that metformin can accumulate in tissues at concentrations several-fold higher than those in blood [19] , caution must be therefore applied when extrapolating our current in vitro results into clinical practice. Nevertheless, it is reasonable to suggest that, in combination with conventional chemotherapy and HER2-targeting agents, metformin co-treatment may add an important therapeutic benefit in debulking and in targeting tumor-initiating cells of HER2-overexpressing BC [20, 21] . Although it remains to be elucidated which metformin-sensitive molecular mechanisms control the maintenance and survival of Tzbresistance HER2-gene-amplified tumor initiating cells, crucial evidence of the clinical efficacy of MET could be obtained from ''proof-of-principle'' studies with neoadjuvant regimens including neoadjuvant chemotherapy (to target bulk BC cells) and Tzb with MET (both targeting self-renewal and proliferation of tumor-initiating cells) in women diagnosed with HER2-positive primary BC [22] .
